You are here: Industry Insights > Lung Cancer

News List

Tagrisso moves closer towards EU approval for early-stage lung cancer pharmatimes
April 29, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s (AZ) Tagrisso for approval in the EU for the treatment of early-stage lung cancer patients.
Harpoon Therapeutics Doses First Patient with Anti-DLL3 T Cell Engager for Lung Cancer americanpharmaceuticalreview
January 11, 2021
Harpoon Therapeutics announced the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC®, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer (SCLC) and other tumors associated ...
FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer americanpharmaceuticalreview
December 23, 2020
The U.S. Food and Drug Administration (FDA) approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
Green light for AZ’s Tagrisso in early-stage lung cancer pharmatimes
December 22, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Tagrisso (osimertinib) for the treatment of adult patient with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
EU to review Merck's targeted lung cancer drug pharmatimes
November 30, 2020
European regulators will review Merck's tepotinib for a specific type of lung cancer, having validated the drug's marketing application.
EMA validates Merck’s application to review tepotinib for lung cancer pharmaceutical-technology
November 30, 2020
The European Medicines Agency (EMA) has validated Merck’s application for reviewing tepotinib as a treatment for adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 ...
AZ’s Tagrisso scores priority review from FDA pharmatimes
October 22, 2020
AstraZeneca’s EGFR-tyrosine kinase inhibitor Tagrisso has been granted a priority review by the US Food and Drug Administration (FDA) for the treatment of early-stage EGFR-mutated lung cancer.
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs prnasia
October 14, 2020
A recent study published in JAMA Network Open has shown that an AI algorithm trained to detect pulmonary nodules can improve lung cancer detection on chest radiographs.
FDA Approves Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer drugs.com
September 23, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection ...
BMS' Opdivo wins new NICE lung cancer backing pharmatimes
September 21, 2020
NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo (nivolumab) as a second-line treatment option for patients with squamous or non-squamous non-small-cell lung cancer (NSCLC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page